{
  "meta": {
    "data_length": 1,
    "message": "Therapy group id txgrp:54 retrieved successfully",
    "request_url": "https://api.moalmanac.org/therapy_groups?therapy_group_id=txgrp%3A54",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001964,
    "timestamp_received": "2026-10-16T23:35:09.329833+00:00Z",
    "timestamp_returned": "2026-10-16T23:35:09.331797+00:00Z",
    "trace_id": "d15f04eb-e9ab-4306-95b4-184dc08e4a76"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "txgrp:54",
      "membershipOperator": "AND",
      "therapies": [
        {
          "id": "tx:ncit:C1794",
          "conceptType": "Therapy",
          "name": "Capecitabine",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:194000",
                "code": "194000",
                "name": "capecitabine",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=194000"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1337620",
                "code": "1337620",
                "name": "capecitabine",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1337620"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "Thymidylate synthase inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Chemotherapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C1794",
            "code": "C1794",
            "name": "Capecitabine",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"
            ]
          }
        },
        {
          "id": "tx:ncit:C1181",
          "conceptType": "Therapy",
          "name": "Oxaliplatin",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:32592",
                "code": "32592",
                "name": "oxaliplatin",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=32592"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1318011",
                "code": "1318011",
                "name": "oxaliplatin",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1318011"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "Platinum-based chemotherapy"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Chemotherapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C1181",
            "code": "C1181",
            "name": "Oxaliplatin",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"
            ]
          }
        },
        {
          "id": "tx:ncit:C106432",
          "conceptType": "Therapy",
          "name": "Pembrolizumab",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1547545",
                "code": "1547545",
                "name": "pembrolizumab",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1547545"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:45775965",
                "code": "45775965",
                "name": "pembrolizumab",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/45775965"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "PD-1/PD-L1 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Immunotherapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C106432",
            "code": "C106432",
            "name": "Pembrolizumab",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"
            ]
          }
        },
        {
          "id": "tx:ncit:C1647",
          "conceptType": "Therapy",
          "name": "Trastuzumab",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:224905",
                "code": "224905",
                "name": "trastuzumab",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=224905"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1387104",
                "code": "1387104",
                "name": "trastuzumab",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1387104"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "HER2 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C1647",
            "code": "C1647",
            "name": "Trastuzumab",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"
            ]
          }
        }
      ]
    }
  ]
}